Last reviewed · How we verify
dexemedetomidine and rocuronium
Dexemedetomidine is a selective alpha-2 adrenergic agonist that provides sedation and analgesia, while rocuronium is a neuromuscular blocking agent that paralyzes skeletal muscles.
Dexemedetomidine is a selective alpha-2 adrenergic agonist that provides sedation and analgesia, while rocuronium is a neuromuscular blocking agent that paralyzes skeletal muscles. Used for Procedural sedation and anesthesia support (phase 3 investigational).
At a glance
| Generic name | dexemedetomidine and rocuronium |
|---|---|
| Sponsor | South Valley University |
| Drug class | Sedative-analgesic and neuromuscular blocking agent combination |
| Target | Alpha-2 adrenergic receptor (dexemedetomidine); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium) |
| Modality | Small molecule |
| Therapeutic area | Anesthesia and Sedation |
| Phase | Phase 3 |
Mechanism of action
Dexemedetomidine binds to alpha-2 adrenergic receptors in the central nervous system to produce dose-dependent sedation, analgesia, and anxiolysis without respiratory depression. Rocuronium competitively blocks acetylcholine at the neuromuscular junction, causing reversible skeletal muscle paralysis. Together, this combination is used for procedural sedation and anesthesia support.
Approved indications
- Procedural sedation and anesthesia support (phase 3 investigational)
Common side effects
- Hypotension
- Bradycardia
- Hypertension
- Muscle weakness or paralysis (expected pharmacologic effect)
- Respiratory depression or apnea
Key clinical trials
- Rapid Sequence Induction: Succinyl Choline vs Rocuronium After Pretreatment With Dexmedetomidine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |